248 related articles for article (PubMed ID: 32050313)
1. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization.
Lee JS; Choi HJ; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baek SE; Chung YE; Park MS; Kim MJ; Rhee H; Kim SU
Gut Liver; 2020 Nov; 14(6):765-774. PubMed ID: 32050313
[TBL] [Abstract][Full Text] [Related]
2. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma.
Lim TS; Rhee H; Kim GM; Kim SU; Kim BK; Park JY; Ahn SH; Han KH; Choi JY; Kim DY
J Vasc Interv Radiol; 2019 Aug; 30(8):1194-1200.e1. PubMed ID: 31235408
[TBL] [Abstract][Full Text] [Related]
3. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria.
Ghosn M; Derbel H; Kharrat R; Oubaya N; Mulé S; Chalaye J; Regnault H; Amaddeo G; Itti E; Luciani A; Kobeiter H; Tacher V
Diagn Interv Imaging; 2021 Jan; 102(1):35-44. PubMed ID: 33012693
[TBL] [Abstract][Full Text] [Related]
4. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
[TBL] [Abstract][Full Text] [Related]
5. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
6. Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?
Zhao Y; Duran R; Bai W; Sahu S; Wang W; Kabus S; Lin M; Han G; Geschwind JF
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):433-442. PubMed ID: 29086058
[TBL] [Abstract][Full Text] [Related]
7. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
[TBL] [Abstract][Full Text] [Related]
8. Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization.
Lee JS; Lee HA; Jeon MY; Lim TS; Kim BK; Park JY; Kim DY; Ahn SH; Um SH; Han KH; Seo YS; Kim SU
Eur J Gastroenterol Hepatol; 2020 Jun; 32(6):739-747. PubMed ID: 31764406
[TBL] [Abstract][Full Text] [Related]
9. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
Liu L; Wang W; Chen H; Zhao Y; Bai W; Yin Z; He C; Jia J; Yang M; Xia J; Fan D; Han G
Clin Cancer Res; 2014 Mar; 20(6):1623-31. PubMed ID: 24493832
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma.
Hyun D; Shin SW; Cho SK; Park KB; Park HS; Choo SW; Do YS; Choo IW; Shin JW; Lim SJ
Acta Radiol; 2015 Dec; 56(12):1437-45. PubMed ID: 25480473
[TBL] [Abstract][Full Text] [Related]
11. Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma.
Weng Z; Ertle J; Zheng S; Lauenstein T; Mueller S; Bockisch A; Gerken G; Yang D; Schlaak JF
Oncol Lett; 2013 Dec; 6(6):1707-1712. PubMed ID: 24260066
[TBL] [Abstract][Full Text] [Related]
12. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Jung ES; Kim JH; Yoon EL; Lee HJ; Lee SJ; Suh SJ; Lee BJ; Seo YS; Yim HJ; Seo TS; Lee CH; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
J Hepatol; 2013 Jun; 58(6):1181-7. PubMed ID: 23395691
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma.
Seyal AR; Gonzalez-Guindalini FD; Arslanoglu A; Harmath CB; Lewandowski RJ; Salem R; Yaghmai V
Hepatology; 2015 Oct; 62(4):1111-21. PubMed ID: 25999236
[TBL] [Abstract][Full Text] [Related]
15. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
[TBL] [Abstract][Full Text] [Related]
16. Utility of Early Posttreatment PET/CT Evaluation Using FDG or
Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A
AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448
[No Abstract] [Full Text] [Related]
17. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.
Zhang YQ; Jiang LJ; Wen J; Liu DM; Huang GH; Wang Y; Fan WZ; Li JP
J Vasc Interv Radiol; 2018 Dec; 29(12):1654-1661. PubMed ID: 30396842
[TBL] [Abstract][Full Text] [Related]
18. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.
Tacher V; Lin M; Duran R; Yarmohammadi H; Lee H; Chapiro J; Chao M; Wang Z; Frangakis C; Sohn JH; Maltenfort MG; Pawlik T; Geschwind JF
Radiology; 2016 Jan; 278(1):275-84. PubMed ID: 26131913
[TBL] [Abstract][Full Text] [Related]
20. Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series.
Srinivas S; Rose SC; Al Jammal O; Hsieh LJ; Rockwell HD; Duncan DP; Minocha J; Berman ZT
Cardiovasc Intervent Radiol; 2023 Apr; 46(4):460-469. PubMed ID: 36854903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]